Pulmonary Embolism: Latest Guidelines (2026)

🆕 Most Current Guideline: 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN

Key highlight: Introduces a new AHA/ACC Acute PE Clinical Classification System to replace the older massive/submassive/low-risk terminology, improving precision for risk stratification and therapeutic decision-making.

1. Classification of PE Severity

2. Diagnosis

Pre-test Probability Assessment

• Use Wells Score (dichotomized as non-high ≤6 vs. high >6) or Revised Geneva Score (low <4, intermediate 4–10, high >10)
• Clinical gestalt by experienced physicians is validated and often the most accurate method
• PERC Rule (8 criteria): when clinician's gestalt PTP is low AND all 8 PERC criteria are met, PE can be excluded without further testing — Rosen's Emergency Medicine

PERC Rule Criteria (all 8 must be negative):

D-Dimer

• Use age-adjusted D-dimer (age × 10 µg/L for patients >50 years)
• YEARS algorithm for low-to-intermediate probability: if 0 YEARS criteria + D-dimer <1000 ng/mL, or 1–3 criteria + D-dimer <500 ng/mL → PE excluded
• D-dimer not reliable in pregnancy (though pregnancy-adapted YEARS has some validation)

Imaging

• CT pulmonary angiography (CTPA) is the diagnostic standard for most patients
• V/Q scan: preferred when contrast allergy, renal impairment, or in pregnancy (halved perfusion dose reduces fetal radiation)
• Echocardiography: assesses RV function, guides risk stratification; not for primary diagnosis

3. Treatment

Anticoagulation (Cornerstone of All Risk Groups)

Risk-Stratified Advanced Therapy

High-Risk PE (Obstructive Shock / Arrest)

• Systemic thrombolysis is first-line: Alteplase 100 mg IV over 2 hours (or tenecteplase weight-based bolus)
• ECMO for refractory cases
• Surgical embolectomy for thrombolysis failure or contraindications
• Catheter-based therapies (mechanical thrombectomy, catheter-directed thrombolysis) as alternatives

Intermediate-High Risk PE

• Anticoagulation initially
• Escalate to catheter-directed or systemic thrombolysis if clinical deterioration (hypotension, worsening RV dysfunction)
• PULSAR/PEITHO trial data inform this approach
• 2025 ESVM guideline endorses catheter-based therapy (CDT, mechanical thrombectomy) in experienced centers for submassive PE

Low-Risk PE

• Anticoagulation alone
• Early discharge / outpatient treatment appropriate if:
  • Hemodynamically stable
  • No significant RV dysfunction
  • No severe comorbidities
  • Reliable follow-up and anticoagulant access
  • Use Hestia criteria or sPESI score = 0 to identify candidates

4. Special Populations

Pregnancy

• LMWH is treatment of choice (no DOACs — cross placenta concern; avoid warfarin in 1st trimester)
• Pregnancy-adapted YEARS algorithm shows promise but not yet fully validated for PE exclusion
• V/Q scan preferred over CTPA to minimize breast radiation
• Prophylactic LMWH throughout pregnancy for prior VTE or multiple risk factors — Murray & Nadel's Respiratory Medicine

Cancer-Associated PE

• LMWH traditionally preferred; DOACs (apixaban, rivaroxaban) now acceptable alternatives per recent data
• Duration: typically treatment-length anticoagulation while cancer is active

Subsegmental PE

• Growing recognition that conservative management (no anticoagulation) may be safe in selected low-risk patients with no DVT

5. Duration of Anticoagulation

6. Pulmonary Embolism Response Teams (PERT)

7. Post-PE Follow-up

• Reassess at 3–6 months for CTEPH (chronic thromboembolic pulmonary hypertension)
• Evaluate for post-PE syndrome (functional limitation, dyspnea, reduced quality of life)
• Repeat imaging not routinely required for uncomplicated low-risk PE
• Screen for underlying malignancy (guided by clinical context, not routine CT pan-scan)

Key Recent Guidelines Summary

Bottom line: The 2026 AHA/ACC guideline is the most current and comprehensive reference. Key shifts include a refined clinical classification system, strong preference for DOACs as first-line anticoagulation, expanded role for catheter-based interventions in intermediate-high risk PE, and structured PERT team approach for complex cases.

Sepsis: Latest Guidelines (2026)

🆕 Most Current Guideline: Surviving Sepsis Campaign (SSC) 2026

Key theme: More individualized, stratified care — moving away from one-size-fits-all protocols toward clinical phenotyping and dynamic assessment.

1. Definition (Sepsis-3, still current)

2. Screening & Recognition

• NEWS/NEWS2 is the recommended early warning score — supersedes qSOFA per 2026 SSC
• SOFA score remains the standard for diagnosing organ dysfunction
• Lactate ≥2 mmol/L flags tissue hypoperfusion even in the absence of overt hypotension ("cryptic shock")
• Early identification of source of infection is mandatory and drives empiric antibiotic selection

3. Antimicrobial Therapy 🆕 Major 2026 Change

Stratified Antibiotic Timing (New for 2026)

This replaces the previous blanket "give antibiotics within 1 hour" for all suspected sepsis, reducing antibiotic overuse.

Antibiotic Selection

• Prolonged β-lactam infusions (extended/continuous infusion) recommended to optimize pharmacokinetics
• Antibiotic de-escalation should be performed once culture data available — antibiotic stewardship principle
• Source control as early as possible (drain abscess, remove infected catheter, surgical debridement for necrotizing fasciitis) — Harrison's 22e

4. Hemodynamic Resuscitation

Fluids

• Initial resuscitation: Up to 30 mL/kg IV crystalloid in the first 3 hours for septic shock (ESICM 2025 guideline: this remains conditional, very low certainty)
• Balanced crystalloids (e.g., Lactated Ringer's, Plasmalyte) preferred over normal saline — reduced risk of hyperchloremic acidosis and AKI
• Colloids/albumin: Not routine; may be considered in refractory cases
• Dynamic assessment of fluid responsiveness (passive leg raise, pulse pressure variation, stroke volume variation) preferred over static measures (CVP) for guiding resuscitation — 2026 SSC upgrade
• Fluid removal (de-resuscitation) after the acute phase — a new 2026 SSC addition recognizing harm of fluid overload

Blood Pressure Targets

• MAP ≥65 mmHg as initial target
• Higher MAP targets (70–80 mmHg) may be appropriate in older adults with chronic hypertension — new 2026 SSC statement
• Reassess frequently using clinical perfusion markers (lactate, urine output, skin perfusion)

5. Vasopressors 🆕 Updated 2026

2026 change: Peripheral vasopressor use is now supported as an acceptable alternative to central venous access in the early resuscitation phase — reducing delays to treatment.

2026 change: Concurrent early vasopressor initiation alongside fluid resuscitation is endorsed for unstable shock — no longer strictly "fluids first."

6. Corticosteroids

• Hydrocortisone 200 mg/day IV (continuous infusion or divided doses) for septic shock not responding to fluids and vasopressors
• Reduces vasopressor requirements and ICU length of stay; mortality benefit remains modest
• Fludrocortisone 50 µg/day may be added (oral/NG) — moderate evidence (APROCCHSS trial)
• Not recommended routinely in sepsis without shock

7. Oxygen & Ventilation

• Target SpO₂ 94–98% (avoid hyperoxia)
• If mechanical ventilation required:
  • Low tidal volume (6 mL/kg predicted body weight) for ARDS
  • Plateau pressure ≤30 cmH₂O
  • Prone positioning ≥16 hrs/day for moderate-severe ARDS (PaO₂/FiO₂ <150)
  • Conservative oxygen strategy (avoid FiO₂ >0.6 once patient stabilized)

8. Additional Supportive Measures

9. Post-Sepsis Care 🆕 New 2026 Focus Area

• Assess for Post-Intensive Care Syndrome (PICS): cognitive impairment, psychiatric disorders (PTSD, anxiety, depression), and physical weakness
• Structured ICU follow-up clinics recommended
• Psychological and physical rehabilitation plans should be initiated before hospital discharge
• Evaluate for underlying immunosuppression or undiagnosed malignancy in patients with unusual or recurrent sepsis episodes

10. Pediatric Sepsis — 2026 SSC Pediatric Update

• Initial fluid bolus 10–20 mL/kg (titrated) rather than 30 mL/kg
• Emphasis on early vasopressor use (epinephrine or dopamine) in resource-limited settings

Summary of Key 2026 SSC Changes vs. 2021

Key References

Bottom line: The 2026 SSC guideline is the current gold standard. The biggest paradigm shifts are stratified antibiotic timing (not all suspected sepsis needs immediate antibiotics), NEWS2 over qSOFA for screening, peripheral vasopressors as an acceptable early route, and a new focus on de-resuscitation and post-sepsis rehabilitation.